Ultimately the problem is they aren't providing enough information. Lighthouse could be correct but the data isn't there to support it and there is no reason why they can't say performance based or the words "up to 120m"...

Who knows....

Then just say performance based...but it doesn't....Its a flat fee...it does seem to say that....

Why doesn't it say that then? Would be simple...Do they take phone calls yet? They didn't before....Someone should ask.

Hey DD...WHat is it the bashers are saying about the NHS deal and payments owed. Being lazy and don't want to dig through it all....

Yeah....kind of funny when Elite is doing what the SEC requires and normal companies do and folks can't seem to grasp basic concepts....

This was a phenomenal Q report.

That is obviously false....but you can believe what you want....

The real question is what is the next drug about to hit Ph3...seems they have plenty of cash and will be loaded up with the next milestone payment too....

Eli 201, 202 hmmmmm....

Elite Pharmaceuticals, Inc. Reports Record Revenues for First Quarter of Fiscal Year 2016 - See more at: http://globenewswire.com/news-release/2015/08/10/759488/10145466/en/Elite-Pharmaceuticals-Inc-Reports-Record-Revenues-for-First-Quarter-of-Fiscal-Year-2016.html#sthash.Q5tlAOWL.dpuf


NORTHVALE, N.J., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced results for the quarter ended June 30, 2015, the first quarter of its 2016 fiscal year.

Consolidated revenues for the first quarter of Fiscal 2016 were $7.1 million, with operating profits totaling $2.5 million. Revenues consisted of $5 million in milestone payments from the ELI-200 license to Epic Pharma and a record $2.1 million generated from product revenue. The milestone payments are the first of a total $15 million in milestones from the ELI-200 licensing agreement. The license agreement also includes, upon commercialization, royalty payments based on net sales. Elite invested $2.4 million this quarter in clinical trials for ELI-200 and on other product development activities, and net income was $16.1 million. Elite will provide an update on development activities during the conference call.

"I am extremely pleased with the record revenues and operating profit this quarter," commented Nasrat Hakim President and CEO of Elite. "I am also excited that Elite has completed dosing of the efficacy study required for the ELI-200 submission. We will have final results for this trial later this year and we expect to complete our NDA submission for ELI-200 thereafter."

Conference Call Information

Elite's management will host a conference call to discuss the results of operations and provide an update on recent business developments: Company executives will conduct a question and answer session following their remarks.

Date: Tuesday, August 11, 2015
Time: 11:00 a.m. EDT
Webcast (live and archive) & Audio Replay: http://ir.elitepharma.com/events_presentations
Dial-in numbers: 800-346-7359 (domestic)
973-528-0008 (international)
Conference number: 98840
The financial statements can be viewed in Elite's First Quarter Report on Form 10-Q here.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and a product under review pending approval by the FDA. Elite's lead pipeline products include abuse-deterrent opioids which utilize the Company's patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.), and a Hong Kong based company for development of a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, its ability to obtain FDA approval of the transfers of the ANDAs or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These risks and other factors, including, without limitation, the Company's ability to obtain sufficient funding under the LPC Agreement or from other sources, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, and the Company's ability to operate as a going concern, are discussed in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q and 8-K. Elite undertakes no obligation to update any forward-looking statements.

- See more at: http://globenewswire.com/news-release/2015/08/10/759488/10145466/en/Elite-Pharmaceuticals-Inc-Reports-Record-Revenues-for-First-Quarter-of-Fiscal-Year-2016.html#sthash.Q5tlAOWL.dpuf

By this time....you mean something different then every time before and what the SEC requires because what you are stating is obviously false...Not sure why you keep stating it since I just posted the information from the SEC and you can look up the previous Q reports.

http://www.sec.gov/answers/form10q.htm

Just to clear up the misinformation below...or you can check the other Q reports from Elite to see same

Form 10-Q
The federal securities laws require publicly traded companies to disclose information on an ongoing basis. For example, domestic issuers must submit annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K for a number of specified events and must comply with a variety of other disclosure requirements.

The Form 10-Q includes unaudited financial statements and provides a continuing view of the company's financial position during the year. The report must be filed for each of the first three fiscal quarters of the company's fiscal year.

In September 2002, the SEC approved a final rule that changed the deadlines for Form 10-K and Form 10-Q for “accelerated filers” -- meaning issuers that have a public float of at least $75 million, that have been subject to the Exchange Act’s reporting requirements for at least 12 calendar months, that previously have filed at least one annual report, and that are not eligible to file their quarterly and annual reports on Forms 10-Q and 10-K using scaled disclosure requirements.

http://www.sec.gov/answers/form10q.htm

Beat me to it...

lol....Yes lets tell the future partners where to start negotiating....sigh..

Glad someone else picked up on that little gem

Glad you accurately understood my reply to you so well....lol...Guess we got lucky there then.

Obviously that is not the deal so maybe you can call into the call instead of someone else here and explain that you misunderstand the deal?

Elites products are at most a few years old and many much more recent. Eli 200 is to be filed and that will generate 15m before one pill is even made.

Then how many other products are pending approval, review transfer etc....?

Quite a few....Its impressive.

Future is incredibly bright...

Based on cash on hand and another big milestone payment coming I am guessing a big trial is also likely coming...if necessary...

That historical information and analysis for the future prospects of the Ph3 trials posted by Dr Lowenstein was clearly false based on what has transpired with Elite. Or Elite is just that good...Or really it is just that this product is rather simple to trial. It is not a miracle drug but just a smart mechanism to deter abuse.

Outstanding 10Q report....big milestone payment with more to come, record product revenues to boot....Very nice stuff

WOW

Once one goes through, the easy buyout will be $2 in my opinion...

The question will be a tough one which is how many do you have ready to go. He already said they have been working on numerous...So stage two could be massive BE trials in addition to the two that were done....

The drugs become slam dunks but I don't think he wants to run a company for years....imo

Elite is working on 17 ADTs. We know three of them right? You can pretty easily figure out what the rest of them are. Now what would just the potential value of a company be with the likely approval be on 17 ADTs?

Here is the bet right now. When FDA approves Eli 200.

The value of ELTP goes up 10 fold. One approval is worth 17 approvals because it validates everything. They have already met with the FDA numerous times. The trials were not needed and then they were. It is a smart and simple concept that is patent protected.

No way you partner now. You do the deal with Epic for manufacturing and cash so no need to sell any more shares at 20-.30 when they are likely worth $1-$2....

When you take a longer view instead of getting wrapped up in the day to day manipulation the plan is becoming smart.

Probably one of the safest long term investments right now with the most upside. Reason being that Opioids relieve pain so efficacy testing is stupid but fine we did the trial anyway. Pharmacological approach is basically fool proof and HAL trial proof more importantly.

And the product is very modular....

So what do we worry about and what is the ceiling? I don't worry about much. And the ceiling is 10x probably maybe more over enough time.

Nah that deal just transfers although I wouldn't be surprised if both were bought at the same time, together. You get large scale manufacturing from Epic who is making nice revenues on their own, have 2x Oxy coming, and you get an entire pipeline from Elite.

They completed the trial and they are ramping up for production of Eli 200. Sounds good to me....And of course results are good. It is a freaking generic opioid with a Naltrexone passenger that is inactive.

I like cheeseburgers....I see the trial stopped recruiting. Should have results soon. Anyone doubt that Oxycodone relieved pain? lol

Dumbest trial but filled a square for the FDA. Question really is......how many more products will the FDA require the same dumb trial? My guess is not many....think about the history of this thing....

I am not sure why I should be mad at AMMX management. They are making deals, bringing in revenue, have bigger deals brewing and are profitable. They are getting the audits done which is great. Niger is Niger. It is happening but will take forever...Been there...done that....It's Africa...things move slowly and are difficult...

I think that is why Lee always notes all the other things going on. He knows not to get to hooked to one deal that may drag on over an undetermined amount of time while he has many other deals getting done...like the one he just did for $2m.

As long as the company is doing great though right? Stock is bad, company is good? hmmmmmmmm

$6m cap....revneues for Q2 and Q3 will be about $6m?

Not counting Niger or other Africa deals? right or wrong?

He sold most long ago imo.....maybe short now or representing some short entity.

Glad its obvious now...

Company needs to do a share buy back from time to time since they are profitable. Wouldnt take much. Its a low floater to begin with. The cap is only about $6m...They will do about $8m this year maybe more, outside of more Niger and other potential Africa deals.

I believe you have successfully proved my point or removed any remaining doubt. Thanks again

Sorry..been AROUND too long to RECOGNIZE manipulation and continued attempts AT manipulation......

PRICE and company success are often not aligned in the short term, but they are in the longTERM.

How many shares do you have?

The company is reporting revenues well in excess of current market cap and is profitable with revenues and profits to be increasing.....

THat is math and I didn't even have to use capital letters.

It also has a small float.

The company is profitable and has real revenue so why would it be kaput? hmmmmmmm

The real question is why someone would say that in caps all the time...hmmm

Curious, who are you working for or are you just short?

or someone selling to knock the price down who has a starting initial of O....lol...pay attention to what is said here and think why..

Then he doesnt know what he is looking at because that makes no sense. He is probably looking at total volume traded for those MMs.

This is false. The float is about that many shares in total

There hasn't been enough volume here or interest. You have traders, not hard to figure out who...here hitting the bid and working the price down...Company is going to have revneue at 4-8x cap maybe more...

Everyone knows this is going to be approved. The red herring here is the attempt to say that Elite did not create some miracle polymer which no one argued in the first place. Their use of the polymer has proven to be novel and unique due to their ability to prove it's unique characteristics in sequestering Naltrexone which was unknown thus they were awarded the patent. The USPTO agrees obviously.

In fact it was demostrated that increases in said polymer showed exponential increases in sequestration effectively shutting down any leakage. The polymers noted by the competition in their inventions were shown to show more of a linear progression which was much more rpoblematic. It was a discovery and in invention. It works and is patented for this use. Elite can also make one bead technology using the same polymer as well.

And reading through all the comments, still waiting for someone to explain how this tech is not going to be extremely successful on any opioid they choose.....